{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:17:45Z","timestamp":1740140265496,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009954","name":"taiho pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10388-021-00905-2","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T13:04:05Z","timestamp":1642683845000},"page":"444-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multicenter phase II study of trifluridine\/tipiracil for esophageal squamous carcinoma refractory\/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study"],"prefix":"10.1007","volume":"19","author":[{"given":"Yukiko","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Horimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harue","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-8203","authenticated-orcid":false,"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Global Burden of Disease Collaboration, Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease study. JAMA Oncol. 2019;5:1749\u201368.","journal-title":"JAMA Oncol"},{"key":"905_CR2","unstructured":"Foundation for Promotion of Cancer Research. Cancer statistics in Japan 2019. https:\/\/ganjoho.jp\/reg_stat\/statistics\/brochure\/backnumber\/2019_jp.html. Accessed 21 Jun 2021"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-020-00785-y","volume":"18","author":"M Watanabe","year":"2021","unstructured":"Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1\u201324.","journal-title":"Esophagus"},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jjco\/hye090","volume":"31","author":"K Hayashi","year":"2001","unstructured":"Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301). Radiation Therapy Oncology Group. JAMA. 1999;281:1623\u20137.","journal-title":"JAMA"},{"key":"905_CR6","first-page":"172","volume":"22","author":"T Iizuka","year":"1992","unstructured":"Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1081\/CNV-120022360","volume":"21","author":"SE Anderson","year":"2003","unstructured":"Anderson SE, O\u2019Reilly EM, Kelsen DP, et al. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest. 2003;21:512\u20136.","journal-title":"Cancer Invest"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/annonc\/mdh231","volume":"15","author":"K Muro","year":"2004","unstructured":"Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955\u20139.","journal-title":"Ann Oncol"},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00280-010-1422-x","volume":"67","author":"K Kato","year":"2011","unstructured":"Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67:1265\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/COC.0b013e3181bead92","volume":"33","author":"HJ Shim","year":"2010","unstructured":"Shim HJ, Cho SH, Hwang JE, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil\/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010;33:624\u20138.","journal-title":"Am J Clin Oncol"},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HER Ford","year":"2014","unstructured":"Ford HER, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78\u201386.","journal-title":"Lancet Oncol"},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"13438","DOI":"10.18632\/oncotarget.24412","volume":"9","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Nakagawa F, Kobunai T, et al. Trifluridine\/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget. 2018;9:13438\u201350.","journal-title":"Oncotarget"},{"key":"905_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1:235\u201348.","journal-title":"Nat Cancer"},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"key":"905_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-016-3179-3","volume":"78","author":"M Nomura","year":"2016","unstructured":"Nomura M, Iwasa S, Tsushima T, et al. Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane. Cancer Chemother Pharmacol. 2016;78:1209\u201316.","journal-title":"Cancer Chemother Pharmacol"},{"key":"905_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"905_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-016-0551-7","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1\u201336.","journal-title":"Esophagus"},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10388-016-0556-2","volume":"14","author":"Japan Esophageal Society","year":"2017","unstructured":"Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37\u201365.","journal-title":"Esophagus"},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(17)30181-X","volume":"18","author":"T Kudo","year":"2017","unstructured":"Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631\u20139.","journal-title":"Lancet Oncol"},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol"},{"key":"905_CR22","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138\u201348.","journal-title":"J Clin Oncol"},{"key":"905_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1535-7163.MCT-19-0918","volume":"19","author":"S Ohashi","year":"2020","unstructured":"Ohashi S, Kikuchi O, Nakai Y, et al. Synthetic lethality with trifluridine\/tipiracil and checkpoint kinase 1 inhibitor for esophageal squamous cell carcinoma. Mol Cancer Ther. 2020;19:1363\u201372.","journal-title":"Mol Cancer Ther"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-021-00905-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-021-00905-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-021-00905-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T06:20:31Z","timestamp":1654237231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-021-00905-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s10388-021-00905-2","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"type":"print","value":"1612-9059"},{"type":"electronic","value":"1612-9067"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Yukiko Mori received honoraria from Daiichi Sankyo and Nipponkayaku. Osamu Kikuchi declares that he has no conflict of interest. Takahiro Horimatsu declares that he has no conflict of interest. Hiroki Hara received grants from Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Elevar Therapeutics, GSK, Incyte, Merck Biopharma, MSD, Ono, Pfizer, and Taiho, consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Lilly, MSD, Ono, honoraria from Bayer, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD, Ono, Sanofi, Taiho, Takeda, and Yakult. Shuichi Hironaka received research funding and honoraria from Taiho. Takashi Kojima received grants from MSD, Ono, Bristol-Myers Squibb, Astellas Amgen BioPharma, Taiho Pharmaceutical, Chugai, and Shionogi and received honoraria from Ono, Bristol-Myers Squibb, MSD, Astellas Pharma, Merk, and Oncolys BioPharma. Ken Kato received research funding from Ono, participation on a Data Safety Monitoring Board or Advisory Board for Bristol-Myers Squibb, MSD, and Roche, and was a leadership or fiduciary role on other boards, society, join committees, or advocacy groups for BMS, MSD, and BeiGene. Takahiro Tsushima declares that he has no conflict of interest. Ryu Ishihara declares that he has no conflict of interest. Kumi Mukai declares that she has no conflict of interest. Ryuji Uozumi received consulting fees from Eisai, Sawai Pharmaceutical, and CAC croit. Harue Tada declares that she has no conflict of interest. Hiroi Kasai declares that she has no conflict of interest. Atsushi Kawaguchi declares that he has no conflict of interest. Manabu Muto received funding support from Taiho.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}